ClinicalTrials.gg
CompletedNCT00636636Updated Feb 22, 2012Results posted

Safety and Efficacy of Gabapentin in Postherpetic Neuralgia

A Phase 3 interventional study of Gabapentin Extended Release tablets and Placebo in Neuralgia,Postherpetic, sponsored by Depomed. Completed at 39 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-22.

Sponsored by Depomed · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 60 studies in Neuralgia, Postherpetic with a site in United States — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia, Postherpetic · United States.

Enrollment
4th of 56
452 · median 93
Started
2008
with 7 others
Phase 3
8 of 60
none open now
Registered
23rd of 60
by date
Lead sponsor
3 of 60
Depomed

Among the 60 studies in Neuralgia, Postherpetic with a site in United States, this one is the 4th largest by enrollment of the 56 interventional ones that give a count, is one of 8 that started in 2008, is one of 8 in phase 3, and was the 23rd registered.

Neuralgia, Postherpetic

197 studies on the registry are indexed under Neuralgia, Postherpetic; 29 are open to participants now.

Browse Neuralgia, Postherpetic studies →

Open to participants now

4 of the 60 studies in Neuralgia, Postherpetic with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Neuralgia, Postherpetic studies recruiting now, 8 (44%) set no upper age limit and 5 (28%) stop at 75 or younger; none take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies in Neuralgia, Postherpetic with a site in United States, or all of them as a file.
02

Study summary

Gabapentin and pregabalin are treatments for some types of neuropathic pain, including postherpetic neuralgia (PHN). However, these treatments usually need to be taken 3 times a day for effective pain control. The purpose of this study is to determine whether a new gabapentin tablet, which only needs to be taken once a day, is safe and effective for the treatment of postherpetic neuralgia.

Read the detailed description

The primary study objective is to assess the relative efficacy of G-ER dosed once daily (1800 mg following the evening meal), versus placebo in reducing the mean daily pain score from the baseline week to the end of the efficacy treatment period (Treatment Week 10) in patients with PHN.

Secondary efficacy measures will include changes from baseline in mean weekly sleep interference scores, Short-Form McGill Pain Questionnaire (SF-MPQ), the Neuropathic Pain Scale (NPS), Brief Pain Inventory (BPI), Patient Global Impression of Change (PGIC), and Investigator-Rated Clinical Global Impression of Change (CGIC).

03

Conditions studied

  • Neuralgia,Postherpetic

Keywords

  • Postherpetic Neuralgia (PHN), shingles
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men or women 18 years or older who have experienced pain for at least 6 months, but not more than 5 years after the healing of a herpes zoster skin rash(typically about 4 months after the rash first appears).
  2. Patient has a pain intensity score of at least 4 on the 11-point Numerical Rating Scale (NRS). Patients should never be informed of the pain intensity criterion prior to screening or randomization.
  3. Patients of must have a negative serum pregnancy test at screening and a negative follow-up urine pregnancy test at randomization.
  4. Patient has a mean baseline week pain intensity score of at least 4 on the 11-point NRS scale at the end of a 1-week baseline period and has completed at least 4 days of daily pain diary entries during the baseline week.
  5. Patients must have a minimum of greater than 5 times the half-life of the drug of several medications.
  6. Patients currently treated with gabapentin pr pregabalin at screening may be eligible for the study, but must have a tapering period wherein the dose of gabapentin or pregabalin is reduced gradually over a period of 5 days followed by a two day washout prior to the Baseline Week.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have previously not responded to treatment for PHN with gabapentin or pregabalin.
  2. Patients who previously experienced dose-limiting adverse effects that prevented titration of gabapentin to an effective dose.
  3. Patient is a nursing mother.
  4. Patient has to gabapentin.
  5. Patient has had neurolytic or neurosurgical treatment for PHN.
  6. Patient has severe pain from causes other than PHN.
  7. Patient has used injected anesthetics or within 30 days of baseline.
  8. Patient has skin conditions in the area affected by the neuropathy that could alter sensation.
  9. Patient is in an state.
  10. Patient has an estimated less than 50 ml/min.
  11. Patient has had within past 2 years other than basal cell carcinoma.
  12. Patient has had gastric reduction surgery.
  13. Patient has severe chronic diarrhea, chronic constipation [unless attributed to drugs that will be washed out], uncontrolled irritable bowel syndrome (IBS) or unexplained weight loss.
  14. Patient has any abnormal chemistry or hematology results that are deemed by the investigator to be .
  15. Patient has a history of substance abuse within the past year.
  16. Patient has a history of seizure (except for infantile febrile seizure) or is at risk of seizure due to head trauma.
  17. Patient has a history of chronic or C, hepatitis within the past 3 months, or infection.
  18. Patient has any other clinically significant medical or psychological condition that, in the opinion of the Investigator would jeopardize the safety of the patient or affect the validity of the study results.
  19. Continuing use of any concomitant medication excluded by Inclusion Criterion 5.
  20. Patient has participated in a clinical trial of an drug or device within 30 days of the screening visit.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    G-ER

    Gabapentin - Extended Release

    Drug: Gabapentin Extended Release tablets

  • Placebo comparator
    Placebo

    Sugar pill

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score

    Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).

    Time frame: 10 weeks

Secondary outcomes

  1. Patient Global Impression of Change (PGIC)

    Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).

    Time frame: 10 weeks

  2. Clinical Global Impression of Change (CGIC)

    Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).

    Time frame: 10 weeks

  3. Average Daily Sleep Interference Score

    Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).

    Time frame: 10 weeks

Other outcomes

  1. Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score

    Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10).

    Time frame: 10 weeks

07

Results

Posted Jan 13, 2012

Participant flow

Recruitment period was from March 2008 through May 2009.

Participant flow — Overall Study
MilestoneG-ERPlacebo
Started221231
Safety & efficacy of gabapentin er186194
379186194
Completed185192
Not completed3639
Withdrew: Other reason46
Withdrew: Adverse event198
Withdrew: Lack of efficacy712
Withdrew: Protocol violation22
Withdrew: Lost to follow-up01
Withdrew: Death01
Withdrew: Withdrawal by subject49

Outcome measures

PrimaryMean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score

Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily pain score from baseline to the final week of efficacy treatment period (Week 10).

Time frame:
10 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score
Scores on a scaleG-ERPlacebo
Mean Change in Baseline Observation Carried Forward (BOCF) Average Daily Pain Score-2.12 ± 0.17-1.63 ± 0.16
Statistical analysis
  • G-ER vs Placebo · ANCOVA · p = 0.0125 · Least squares mean difference: -0.49 · 95% CI -0.88 to -0.11
SecondaryPatient Global Impression of Change (PGIC)

Patient self-assessment of how much pain had changed at end of treatment period (Week 10) compared to pain at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).

Time frame:
10 weeks
Reported as:
Number · Participants
Patient Global Impression of Change (PGIC)
ParticipantsG-ERPlacebo
Patient Global Impression of Change (PGIC)9477
Statistical analysis
  • G-ER vs Placebo · Z test · p = 0.0434 · Difference in proportion: 0.092 · 95% CI -0.00 to 0.18
SecondaryClinical Global Impression of Change (CGIC)

Investigator assessment of patient's overall PHN symptoms at end of treatment period (Week 10) compared to overall PHN symptoms at baseline; scored on 7-point numerical rating scale (where 1 = very much improved, 7 = very much worse). Results presented as number of participants categorized at end of treatment (Week 10) as "very much improved" (score = 1) or "much improved" (score = 2).

Time frame:
10 weeks
Reported as:
Number · Participants
Clinical Global Impression of Change (CGIC)
ParticipantsG-ERPlacebo
Clinical Global Impression of Change (CGIC)9778
Statistical analysis
  • G-ER vs Placebo · Z test · p = 0.0268 · Difference in proportion: 0.102 · 95% CI 0.01 to 0.19
SecondaryAverage Daily Sleep Interference Score

Assessed on 11-point numeric rating scale (where 0 = pain does not interfere with sleep, 10 = pain completely interferes with sleep); evaluated from daily sleep entry in electronic diary. Results presented as least squares (LS) mean change in baseline observation carried forward (BOCF) average daily sleep interference score from baseline to final week of treatment period (Week 10).

Time frame:
10 weeks
Reported as:
Least squares mean · Scores on a scale
Average Daily Sleep Interference Score
Scores on a scaleG-ERPlacebo
Average Daily Sleep Interference Score-2.30 ± 0.16-1.59 ± 0.15
Statistical analysis
  • G-ER vs Placebo · ANCOVA · p = 0.0001 · Least square mean difference: -0.71 · 95% CI -1.07 to -0.35P-value versus Placebo for pairwise test of difference of LS mean change from baseline between G-ER and Placebo groups is based on t-test of Type III analysis.
Other pre-specifiedMean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score

Average daily pain scored on 11-point numerical rating scale (where 0 = no pain, 10 = worst possible pain). Results presented as least squares (LS) mean change in last observation carried forward (LOCF) average daily pain score from baseline to final week of efficacy treatment period (Week 10).

Time frame:
10 weeks
Reported as:
Least squares mean · Scores on a scale
Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score
Scores on a scaleG-ERPlacebo
Mean Change in Last Observation Carried Forward (LOCF) Average Daily Pain Score-2.40 ± 0.17-1.85 ± 0.17
Statistical analysis
  • G-ER vs Placebo · ANCOVA · p = 0.007 · Least square mean difference: -0.55 · 95% CI -0.96 to -0.15

Adverse events

Collected over 11 weeks (plus 30 days for SAEs). Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
G-ER—4/221 (1.8%)92/221 (41.6%)
Placebo—6/231 (2.6%)63/231 (27.3%)
Most frequent serious events
Most frequent serious events
EventG-ERPlacebo
Left arm fractureMusculoskeletal and connective tissue disorders1/2211/231
OsteochondrosisMusculoskeletal and connective tissue disorders1/2210/231
Pancoast tumorRespiratory, thoracic and mediastinal disorders1/2210/231
Pancreatitis chronicGastrointestinal disorders1/2210/231
Cardiac failure congestionCardiac disorders0/2211/231
CellulitisSkin and subcutaneous tissue disorders0/2211/231
HematuriaRenal and urinary disorders0/2211/231
Myocardial infarctionCardiac disorders0/2211/231
ThrombophlebitisVascular disorders0/2211/231
Most frequent other events
Showing 10 of 17
Most frequent other events
EventG-ERPlacebo
DizzinessNervous system disorders25/2214/231
SomnolenceNervous system disorders12/2217/231
HeadacheNervous system disorders10/2219/231
NauseaGastrointestinal disorders10/2217/231
Peripheral edemaGeneral disorders7/2211/231
DiarrheaGastrointestinal disorders6/2215/231
Abdominal pain upperGastrointestinal disorders3/2216/231
NasopharyngitisInfections and infestations5/2216/231
Dry mouthGastrointestinal disorders4/2212/231
DyspepsiaGastrointestinal disorders4/2211/231

Baseline characteristics

Age Continuous
Age Continuous(years)G-ERPlaceboTotal
Mean65.3 ± 13.365.9 ± 11.165.6 ± 12.2
Age, Customized
Age, Customized(participants)G-ERPlaceboTotal
<65 years8189170
65 to 74 years8286168
>=75 years5755112
Sex: Female, Male
Sex: Female, Male(Participants)G-ERPlaceboTotal
Female134147281
Male8683169
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)G-ERPlaceboTotal
Caucasian196204400
Black10616
Asian123
Other131831
08

Study locations

39 sites
  • Birmingham, Alabama, United States
  • Tuscaloosa, Alabama, United States
  • Phoenix, Arizona, United States
  • Little Rock, Arkansas, United States
  • Lancaster, California, United States
  • Los Angeles, California, United States
  • Pismo Beach, California, United States
  • Colorado Springs, Colorado, United States
  • Pueblo, Colorado, United States
  • Daytona Beach, Florida, United States
  • Naples, Florida, United States
  • New Port Richey, Florida, United States
  • Orlando, Florida, United States
  • Tampa, Florida, United States
  • Marietta, Georgia, United States
  • Honolulu, Hawaii, United States
  • Elk Grove Village, Illinois, United States
  • Shreveport, Louisiana, United States
  • West Yarmouth, Massachusetts, United States
  • Ann Arbor, Michigan, United States
  • Florissant, Missouri, United States
  • Jefferson City, Missouri, United States
  • Albuquerque, New Mexico, United States
  • High Point, North Carolina, United States
  • Bismarck, North Dakota, United States
  • Fargo, North Dakota, United States
  • Canton, Ohio, United States
  • Cincinnati, Ohio, United States
  • Kettering, Ohio, United States
  • Warwick, Rhode Island, United States
  • Murrells Inlet, South Carolina, United States
  • Pelzer, South Carolina, United States
  • Tullahoma, Tennessee, United States
  • Austin, Texas, United States
  • Longview, Texas, United States
  • Spokane, Washington, United States
  • Buenos Aires, Argentina
  • All over Russia, Russian Federation
  • St. Petersburg, Russian Federation
09

References and documents

Publications

  • Mehta N, Bucior I, Bujanover S, Shah R, Gulati A. Relationship between pain relief, reduction in pain-associated sleep interference, and overall impression of improvement in patients with postherpetic neuralgia treated with extended-release gabapentin. Health Qual Life Outcomes. 2016 Apr 1;14:54. doi: 10.1186/s12955-016-0456-0. PubMed 27037091 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2008, a primary completion of Aug 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jan 2012, 2 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2008
First posted
Mar 14, 2008
Start
Mar 2008
Primary completionActual
Aug 2009
CompletionActual
Sep 2009
Results first posted
Jan 13, 2012
Last update
Feb 22, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 22, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00636636
Lead sponsor
Depomed
Responsible party
Sponsor
First posted
Mar 14, 2008
Start date
Mar 2008
Primary completion
Aug 2009
Completion
Sep 2009
Results posted
Jan 13, 2012
Last update
Feb 22, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gabapentin

Start the discussion